ストックスクリーナーアプリを入手
14.73
0.61%
0.09
アフターアワーズ：
14.84
0.11
+0.75%
前日終値:
$14.64
開ける：
$14.67
24時間の取引高:
1.03M
Relative Volume:
0.52
時価総額：
$885.98M
収益：
$439.00K
当期純損益:
$-105.64M
株価収益率:
-8.1833
EPS:
-1.8
ネットキャッシュフロー:
$-60.70M
1週間 パフォーマンス:
+12.02%
1か月 パフォーマンス:
+3.37%
6か月 パフォーマンス:
-43.26%
1年 パフォーマンス:
-66.17%
1日の値動き範囲:
$14.54
$15.04
1週間の範囲:
$13.11
$15.49
52週間の値動き範囲:
$12.80
$46.09
Janux Therapeutics Inc Stock (JANX) Company Profile
名前
Janux Therapeutics Inc
セクター
電話
(858) 751-4493
住所
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
JANX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
14.73 | 880.56M | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-10 | 開始されました | Stifel | Buy |
| 2025-09-10 | 開始されました | Truist | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-07-11 | 開始されました | Raymond James | Outperform |
| 2024-12-03 | 繰り返されました | BTIG Research | Buy |
| 2024-12-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-11-22 | 開始されました | Leerink Partners | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-09-06 | 開始されました | Stifel | Buy |
| 2024-05-30 | 開始されました | Scotiabank | Sector Perform |
| 2024-03-21 | 開始されました | BTIG Research | Buy |
| 2024-03-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 開始されました | Wedbush | Outperform |
| 2022-11-14 | 開始されました | William Blair | Outperform |
すべてを表示
Janux Therapeutics Inc (JANX) 最新ニュース
Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy - Yahoo Finance
Janux Therapeutics appoints William Go as new chief medical officer By Investing.com - Investing.com Nigeria
Janux Therapeutics (NASDAQ:JANX) Shares Gap DownShould You Sell? - MarketBeat
Janux Therapeutics Taps Dr. William Go as Chief Medical Officer - Contract Pharma
Janux Therapeutics appoints William Go as new chief medical officer - Investing.com
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - Business Wire
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion (BMY) - Seeking Alpha
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Price-Driven Insight from (JANX) for Rule-Based Strategy - Stock Traders Daily
JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Finviz
Janux Therapeutics Inks Global Oncology Collaboration With BMS - TipRanks
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - wsau.com
Janux Therapeutics Signs Exclusive License and Collaboration Agreement With Bristol-Myers Squibb - TradingView
Janux Therapeutics (NASDAQ:JANX) Sees Strong Trading VolumeHere's Why - MarketBeat
Janux Therapeutics Pairs With BMS on Novel Tumor-Activated Therapeutic - Contract Pharma
Key facts: Bristol Myers Squibb signs $850M deal with Janux; partners with Microsoft for AI - TradingView
BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy - MedCity News
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
BMS bets on Janux’s novel solid tumour therapy through $850m deal - Yahoo Finance
Janux Therapeutics, Inc. Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop A Novel Tumor-Activated Therapeutic for Solid Tumors - marketscreener.com
Bristol Myers buys into Janux’s ‘masked’ T cell engagers - BioPharma Dive
Janux, Bristol Myers Squibb partner on tumor-activated therapy By Investing.com - Investing.com Canada
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - BioSpace
Janux stock rises after Bristol Myers Squibb collaboration deal By Investing.com - Investing.com UK
Janux stock rises after Bristol Myers Squibb collaboration deal - Investing.com
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments - BioSpace
Janux Therapeutics Secures Exclusive License Agreement with Bristol Myers Squibb, Potential Earnings Up to $800 Million - Intellectia AI
Bristol Myers (BMY) Partners with Janux Therapeutics on Cancer T - GuruFocus
Janux Shares Rise On Solid Tumor License Agreement with Bristol Myers Squibb - marketscreener.com
Bristol Myers inks licensing deal with Janux for cancer therapy - Seeking Alpha
Janux Therapeutics stock soars after Bristol Myers Squibb collaboration By Investing.com - Investing.com Canada
Janux Therapeutics, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor Therapy - TradingView
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Janux Therapeutics (JANX) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Clear Str Downgrades Janux Therapeutics (NASDAQ:JANX) to Hold - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Reaches New 1-Year LowWhat's Next? - MarketBeat
Clear Street downgrades Janux Therapeutics stock to Hold on efficacy concerns - Investing.com Canada
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - MarketBeat
JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target - MSN
Energy Moves: Is Janux Therapeutics Inc part of any ETFQuarterly Market Review & Expert Approved Momentum Ideas - baoquankhu1.vn
Volume Report: What is Janux Therapeutics Inc. s debt to equity ratioJuly 2025 Price Swings & Risk Controlled Daily Plans - baoquankhu1.vn
Moving Averages: How Janux Therapeutics Inc stock reacts to oil pricesWatch List & Advanced Swing Trade Entry Alerts - Bộ Nội Vụ
Risk Report: Can Janux Therapeutics Inc stock reach 100 price targetJuly 2025 Update & Daily Growth Stock Tips - Bộ Nội Vụ
Treasury Yields: Can Janux Therapeutics Inc stock reach 100 price targetWeekly Risk Report & Real-Time Market Sentiment Reports - Bộ Nội Vụ
(JANX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Pullback Watch: Will Janux Therapeutics Inc stock maintain dividend yieldJuly 2025 Weekly Recap & Daily Entry Point Trade Alerts - Bộ Nội Vụ
Will Janux Therapeutics Inc. stock maintain dividend yield2025 Stock Rankings & Capital Efficiency Focused Ideas - Улправда
Aug Retail: Will Janux Therapeutics Inc. stock benefit from upcoming earnings reportsWeekly Trend Summary & Fast Exit Strategy with Risk Control - Улправда
Can Janux Therapeutics Inc. stock deliver sustainable ROEAnalyst Upgrade & Safe Swing Trade Setup Alerts - Улправда
Janux Therapeutics Inc (JANX) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):